Anti-proliferative effect of melatonin in human hepatoma HepG2 cells occurs mainly through cell cycle arrest and inflammation inhibition

• Published in: Scientific reports Vol. 13; no. 1; p. 4396
• Main Authors: Nabih, Heba K., Hamed, Ahmed R., Yahya, Shaymaa M. M.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 16-03-2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/337; 631/45; Anti-inflammatory agents; Apoptosis; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - metabolism; Cell Cycle; Cell Cycle Checkpoints - drug effects; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Drug dosages; Drug resistance; Flow cytometry; G1 phase; Genes; Hep G2 Cells; Hepatocellular carcinoma; Hepatoma; Humanities and Social Sciences; Humans; Inflammation; Inflammation - drug therapy; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - metabolism; Melatonin; Melatonin - pharmacology; Melatonin - therapeutic use; multidisciplinary; p53 Protein; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-31443-9

Hepatocellular carcinoma (HCC) is the major lethal primary liver malignant worldwide. Although, melatonin has various antitumor bioactivities; there is a requirement for more investigations to elucidate the not discussed effects, and the controversial responses of the treatment with melatonin on targets mediated in HCC. To achieve the aim of the present study, HCC-HepG2 cells were treated with different concentrations of melatonin at various time intervals. The selected minimal proliferation inhibition doses of melatonin were then incubated with cells to examine the arresting effect of melatonin on dividing cells using flow cytometry. Furthermore, the molecular patterns of genes that contributed to apoptosis, drug resistance development, antioxidation, and melatonin crossing were quantified by qRT-PCR. Additionally, the Human inflammation antibody array membrane (40 targets) was used to check the anti-inflammatory effect of melatonin. Our results validated that, melatonin shows anti-proliferative action through preserving cells in G0/G1 phase (
P
 < 0.001) that is associated with a highly significant increase in the expression level of the P53 gene (
P
 < 0.01). On contrary, as a novelty, our data recorded decreases in expression levels of genes involved in the pro-apoptotic pathway; with a significant increase (
P
 < 0.05) in the expression level of an anti-apoptotic gene, Bcl2. Interestingly, we detected observed increases in the expression levels of genes responsible for conferring drug resistance including ABCB1, ABCC1, and ABCC5. Our study proved the anti-inflammatory activity of 1 mM melatonin in HCC-HepG2 cells. Accordingly, we can conclude that melatonin facilitates the anti-proliferation of cells at doses of 1 mM, and 2.5 mM after 24 h. This action is initiated through cell cycle arrest at G0/G1 phase via increasing the expression of P53, but independently on apoptosis. Collectively, melatonin is an effective anti-inflammatory and anti-proliferative promising therapy for the treatment of HCC. However, its consumption should be cautious to avoid the development of drug resistance and provide a better treatment strategy.